1. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease
   Sarah Bayne et al, 2024, Advanced Biology CrossRef
2. Integrin β3 overexpression contributes to podocyte injury through inhibiting RhoA/YAP signaling pathway
   Zhuo Li et al, 2021, Bioengineered CrossRef
3. TGF-β1 modulates podocyte migration by regulating the expression of integrin-β1 and -β3 through different signaling pathways
   Chien-An Chen et al, 2018, Biomedicine & Pharmacotherapy CrossRef
4. ISN Forefronts Symposium 2015: Nuclear Receptors and Diabetic Nephropathy
   Bo Zheng et al, 2016, Kidney International Reports CrossRef
5. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
   Daiji Kawanami et al, 2021, Frontiers in Pharmacology CrossRef
6. Role of the sodium‐hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes
   Milton Packer, 2018, Diabetes, Obesity and Metabolism CrossRef
7. A disease model of diabetic nephropathy in a glomerulus-on-a-chip microdevice
   Li Wang et al, 2017, Lab on a Chip CrossRef
8. Role of Transient Receptor Potential Canonical Channel 6 (TRPC6) in Diabetic Kidney Disease by Regulating Podocyte Actin Cytoskeleton Rearrangement
   Qian Wang et al, 2020, Journal of Diabetes Research CrossRef
9. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes
   Dan Dong et al, 2019, International Urology and Nephrology CrossRef
10. HDAC6‐mediated α‐tubulin deacetylation suppresses autophagy and enhances motility of podocytes in diabetic nephropathy
    Tiantian Liang et al, 2020, Journal of Cellular and Molecular Medicine CrossRef
11. Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
    Jonatan Barrera-Chimal et al, 2022, Nature Reviews Nephrology CrossRef
12. Urolithin A Ameliorates the TGF Beta-Dependent Impairment of Podocytes Exposed to High Glucose
    Barbara Lewko et al, 2024, Journal of Personalized Medicine CrossRef